Millennium Names Peter F. Smith Senior Vice President of Preclinical Drug Development

Apr 19, 2001, 01:00 ET from Millennium Pharmaceuticals, Inc.

    CAMBRIDGE, Mass., Apr. 19 /PRNewswire/ -- Millennium Pharmaceuticals, Inc.
 (Nasdaq:   MLNM) today announced the appointment of Peter F. Smith, Ph.D. to the
 position of senior vice president of preclinical drug development, a newly-
 created position.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
     Dr. Smith will lead a preclinical group charged with insuring a smooth
 transition from discovery to development in the areas of toxicology and
 pathology, metabolism and pharmacokinetics, and building interfaces with all
 related disciplines.  In addition, Dr. Smith will work closely with discovery
 and development project teams to expedite selection of potential drug
 candidates and to foster the expeditious development of personalized
 medicines.
     Dr. Smith, 43, brings to Millennium more than 15 years of experience in
 the pharmaceutical industry including expertise in the development of
 pharmaceutical candidates, product safety assessment, and evaluation in
 toxicology and pharmacology.  Most recently, Dr. Smith was vice president of
 global metabolism and investigative sciences at Pharmacia Corporation where he
 led a staff of more than 300 scientists located at five international sites.
 Previously he spent eight years at Searle/Monsanto in positions of increasing
 responsibility, including executive director of the department of metabolism
 and safety evaluation, and senior director of product safety assessment.
     "Millennium is aggressively moving its pipeline downstream from research
 to drug discovery and development, and ultimately to commercialization," said
 Mark Levin, chief executive officer.  "Peter's broad experience in preclinical
 development makes him an outstanding addition to our team as we continue to
 industrialize the research and development process, implement personalized
 medicine and build the biopharmaceutical company of the future."
     "Millennium's unique approach to drug discovery and development is at the
 forefront of the industry," said Dr. Smith.  "Based on Millennium's process of
 identifying new drug targets and the speed and agility with which these
 targets are accessed and converted, it will be a model for the industry for
 many years to come. I welcome the opportunity to be part of such a visionary
 company and look forward to building a highly effective team to creatively
 help discover and develop novel therapeutic agents."
     Millennium, a leading biopharmaceutical company, applies its comprehensive
 and integrated science and technology platform for the discovery and
 development of breakthrough therapeutic and predictive medicine products, with
 a goal of delivering personalized medicine.  Through the industrialization of
 this gene-to-patient platform, Millennium is also striving to accelerate the
 process of drug discovery and development.  Headquartered in Cambridge, Mass.,
 Millennium currently employs more than 1,300 people.
 
     This press release contains "forward-looking statements," including
 statements about our growth and future operating results, discovery and
 development of products, potential acquisitions, strategic alliances and
 intellectual property.  Various risks may cause Millennium's actual results to
 differ materially, including: adverse results in our drug discovery and
 clinical development processes; failure to obtain patent protection for our
 discoveries; commercial limitations imposed by patents owned or controlled by
 third parties; our dependence upon strategic alliance partners to develop and
 commercialize products and services based on our work; difficulties or delays
 in obtaining regulatory approvals to market products and services resulting
 from our development efforts; and the requirement for substantial funding to
 conduct research and development and to expand commercialization activities.
 For a further list and description of the risks and uncertainties we face, see
 the reports we have filed with the Securities and Exchange Commission.  We
 disclaim any intention or obligation to update or revise any forward-looking
 statements, whether as a result of new information, future events or otherwise
 
     Editor's Note: This release is available on Millennium's Web site at:
 www.millennium.com
 
 

SOURCE Millennium Pharmaceuticals, Inc.
    CAMBRIDGE, Mass., Apr. 19 /PRNewswire/ -- Millennium Pharmaceuticals, Inc.
 (Nasdaq:   MLNM) today announced the appointment of Peter F. Smith, Ph.D. to the
 position of senior vice president of preclinical drug development, a newly-
 created position.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
     Dr. Smith will lead a preclinical group charged with insuring a smooth
 transition from discovery to development in the areas of toxicology and
 pathology, metabolism and pharmacokinetics, and building interfaces with all
 related disciplines.  In addition, Dr. Smith will work closely with discovery
 and development project teams to expedite selection of potential drug
 candidates and to foster the expeditious development of personalized
 medicines.
     Dr. Smith, 43, brings to Millennium more than 15 years of experience in
 the pharmaceutical industry including expertise in the development of
 pharmaceutical candidates, product safety assessment, and evaluation in
 toxicology and pharmacology.  Most recently, Dr. Smith was vice president of
 global metabolism and investigative sciences at Pharmacia Corporation where he
 led a staff of more than 300 scientists located at five international sites.
 Previously he spent eight years at Searle/Monsanto in positions of increasing
 responsibility, including executive director of the department of metabolism
 and safety evaluation, and senior director of product safety assessment.
     "Millennium is aggressively moving its pipeline downstream from research
 to drug discovery and development, and ultimately to commercialization," said
 Mark Levin, chief executive officer.  "Peter's broad experience in preclinical
 development makes him an outstanding addition to our team as we continue to
 industrialize the research and development process, implement personalized
 medicine and build the biopharmaceutical company of the future."
     "Millennium's unique approach to drug discovery and development is at the
 forefront of the industry," said Dr. Smith.  "Based on Millennium's process of
 identifying new drug targets and the speed and agility with which these
 targets are accessed and converted, it will be a model for the industry for
 many years to come. I welcome the opportunity to be part of such a visionary
 company and look forward to building a highly effective team to creatively
 help discover and develop novel therapeutic agents."
     Millennium, a leading biopharmaceutical company, applies its comprehensive
 and integrated science and technology platform for the discovery and
 development of breakthrough therapeutic and predictive medicine products, with
 a goal of delivering personalized medicine.  Through the industrialization of
 this gene-to-patient platform, Millennium is also striving to accelerate the
 process of drug discovery and development.  Headquartered in Cambridge, Mass.,
 Millennium currently employs more than 1,300 people.
 
     This press release contains "forward-looking statements," including
 statements about our growth and future operating results, discovery and
 development of products, potential acquisitions, strategic alliances and
 intellectual property.  Various risks may cause Millennium's actual results to
 differ materially, including: adverse results in our drug discovery and
 clinical development processes; failure to obtain patent protection for our
 discoveries; commercial limitations imposed by patents owned or controlled by
 third parties; our dependence upon strategic alliance partners to develop and
 commercialize products and services based on our work; difficulties or delays
 in obtaining regulatory approvals to market products and services resulting
 from our development efforts; and the requirement for substantial funding to
 conduct research and development and to expand commercialization activities.
 For a further list and description of the risks and uncertainties we face, see
 the reports we have filed with the Securities and Exchange Commission.  We
 disclaim any intention or obligation to update or revise any forward-looking
 statements, whether as a result of new information, future events or otherwise
 
     Editor's Note: This release is available on Millennium's Web site at:
 www.millennium.com
 
 SOURCE  Millennium Pharmaceuticals, Inc.